8-K: Carisma Therapeutics Announces Upcoming Phase 1 Trial for CT-1119 and Preclinical Liver Fibrosis Program

Carisma Therapeutics plans to initiate a Phase 1 clinical trial of CT-1119 in combination with tislelizumab for solid tumors and advance its liver fibrosis program.

Summary

• Carisma Therapeutics plans to initiate a Phase 1 clinical trial of CT-1119, a mesothelin-targeted CAR-Monocyte, in combination with tislelizumab, an anti-PD-1 antibody, for adult patients with mesothelin-positive solid tumors in the first half of 2025.
• The trial will enroll up to 12 patients in China, with CT-1119 administered in combination with tislelizumab once every three weeks for up to five cycles.
• The primary goal of the Phase 1 trial is to evaluate the safety and tolerability of the combination, with secondary analyses focusing on objective response rate, pharmacokinetics, and correlative studies.
• Initial data from the Phase 1 clinical trial is anticipated in the fourth quarter of 2025.
• The company also plans to conduct preclinical development for its liver fibrosis program in 2025, aiming for a regulatory submission in 2026 and a potential Phase 1 clinical trial initiation in 2026, subject to regulatory clearance.

Sentiment

Score: 7

Explanation: The announcement is moderately positive, outlining planned clinical trials and preclinical development. However, it is tempered by the inherent risks associated with drug development and regulatory approvals.

Positives

• The initiation of a Phase 1 clinical trial for CT-1119 represents progress in Carisma Therapeutics' pipeline.
• Advancing the liver fibrosis program towards a potential clinical trial in 2026 indicates expansion of the company's therapeutic focus.

Risks

• The announcement contains forward-looking statements that are subject to risks and uncertainties, including the ability to initiate, enroll, and advance trials, complete preclinical studies, and obtain regulatory approvals.
• Changes in the macroeconomic environment or competitive landscape could impact the company's business.

Future Outlook

Carisma Therapeutics anticipates initiating a Phase 1 clinical trial of CT-1119 in the first half of 2025 and reporting initial data in the fourth quarter of 2025; they also plan to advance their liver fibrosis program with a regulatory submission potentially in 2026 and a Phase 1 trial in 2026, subject to regulatory clearance.

Industry Context

The announcement reflects the ongoing trend in immuno-oncology of combining CAR-based therapies with checkpoint inhibitors (anti-PD-1 antibodies) to enhance efficacy in solid tumors. The liver fibrosis program aligns with the growing interest in developing therapies for chronic liver diseases.

Stakeholder Impact

• Shareholders may react positively to the planned clinical trial and preclinical development.
• Patients with mesothelin-positive solid tumors and liver fibrosis may benefit from the potential new therapies.
• Employees are likely to be involved in the execution of the clinical trials and preclinical development.

Next Steps

• Initiate Phase 1 clinical trial of CT-1119 in combination with tislelizumab in the first half of 2025.
• Enroll up to 12 patients in China for the CT-1119 trial.
• Report initial data from the CT-1119 Phase 1 clinical trial in the fourth quarter of 2025.
• Conduct preclinical development in the liver fibrosis program in 2025.
• Submit a regulatory submission for the liver fibrosis program in 2026.
• Potentially initiate a Phase 1 clinical trial for the liver fibrosis program in 2026, subject to regulatory clearance.

Key Dates